Since metformin is primarily transported via the OCTs in kidneys, drug interactions related to the inhibition of OCTs, especially OCT2, may be particularly significant for patients with T2DM taking metformin. The gene discussed is SLC22A2; the disease is type 2 diabetes mellitus.